Tempest Therapeutics secured an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and reported a net loss of $3.6 million for Q3 2026. The company also raised approximately $52.5 million through an equity line of credit and private placements to support its cancer and autoimmune disease therapy pipeline. Tempest advanced its lead CAR-T candidates TPST-4903 and TPST-4003, with ongoing Phase 1 trials and upcoming clinical data presentations. Despite a cash balance decline to $0.9 million, Tempest strengthened its board and plans to continue developing its innovative in vivo CAR-T therapies.
Tempest Therapeutics' third quarter 2026 financial results and business update provide context for readers. For those following the health sector, 71 of 150 priced US stocks rose and 75 fell on Pluang today. Notable movers include IONS at USD 29.23 with a 7.03% increase and 100% buy order activity, CNC at USD 75.10 up 6.86%, and AVAH at USD 11.48 down 6.17%. Data is as of Nov 14, 2026 04:11 WIB.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
